目的：探讨孟鲁司特钠及酮替芬在佐治毛细支气管炎的临床疗效。方法将60例毛细支气管炎患儿随机分成A组30例和B组30例，两组均采用相同综合治疗。A组加服孟鲁司特钠，6个月以下2.5 mg/d，6个月以上4 mg/d，每晚服用1次；B组加服酮替芬，6个月以下0.5 mg/d，6个月以上1 mg/d，每晚服用1次；用药疗程至症状和体征消失，观察喘憋、肺部体征改善时间，并对所有病例随访3个月，观察患儿在此期间再次出现喘息的例数及复发率。结果 A组、B组临床有效率分别为93.3%及70.0%，两组相比差异有统计学意义（P<0.05）；A组患儿症状缓解及消失时间均明显短于B组；且A组复发率低于B组，复发时间晚于B组（P<0.05）。结论孟鲁司特钠在佐治毛细支气管炎过程中，对症状缓解及预防喘息再次发作的作用均优于酮替芬，临床值得推广。%Objective To investigate the clinical curative effect of Montelukast and Ketotifen on treating bronchiolitis. Methods 60 cases of bronchiolitis patients were randomly divided into two groups, group A and group B, 30 cases in each group. Both use the same comprehensive treatment. Group A add Montelukast, under 6 months give 2.5 mg/d, 6 months above give 4 mg/d, po, qn;Group B given Ketotifen, under 6 months 0.5 mg/d, above 6 months give 1 mg/d, po, qn. Until the symptoms and signs disappeared, to observe suppress lung signs and improve the time. All cases were followed up for 3 months, observing the cases of children appear again during this period which were wheezing and recurrence rate. Results Clinical effective rate in group A, group B were 93.3%and 70.0%, compared two groups was statistically significant difference (P<0.05);A group of children with ease and disappear time were significantly shorter than group B;and the recurrence rate is lower than group B, group A recurrence time later than group B (P<0.05). Conclusion Montelukast in the process of bronchiolitis to relieve symptoms and prevent breathing again attacks were also better than the Ketotifen, the role of clinical worth extending.
展开▼
